Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
Recently, ATP synthase inhibitor Bedaquiline was approved for the treatment of multi-drug resistant tuberculosis emphasizing the importance of oxidative phosphorylation for the survival of mycobacteria. ATP synthesis is primarily dependent on the generation of proton motive force through the electro...
Main Authors: | Sapna Bajeli, Navin Baid, Manjot Kaur, Ganesh P. Pawar, Vinod D. Chaudhari, Ashwani Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2020.589318/full |
Similar Items
-
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
by: Bei Shi Lee, et al.
Published: (2021-01-01) -
Cytochrome c Oxidase on the Crossroads of Transcriptional Regulation and Bioenergetics
by: Ivan Vladimirovich Chicherin, et al.
Published: (2019-05-01) -
Rcf1 Modulates Cytochrome c Oxidase Activity Especially Under Energy-Demanding Conditions
by: Hannah Dawitz, et al.
Published: (2020-01-01) -
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
by: Iram Khan Iqbal, et al.
Published: (2018-02-01) -
Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content>
by: Caroline S. Foo, et al.
Published: (2018-11-01)